Compositions and methods for treatment of diabetic macular edema

Patent metadata

Field	Value
Publication number	US-12084515-B2
Application number	US-202117345033-A
Country	US
Kind code	B2
Filing date	Jun 11, 2021
Priority date	Mar 27, 2014
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

First claim

What is claimed is:

1. A method for treating a retinal disease in a subject, the method comprising:
administering an effective amount of a composition comprising an antibody that binds to active human plasma kallikrein to a subject in need thereof, wherein the antibody comprises:
(i) a heavy chain variable region comprising a complementarity determining region (CDR) 1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as QRTGVPRRDSFNI (SEQ ID NO: 44), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10);
(ii) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRTGVPRRDEFDI (SEQ ID NO: 46), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10);
(iii) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRIGVPRRDSFDM (SEQ ID NO: 52), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10); or
(iv) a heavy chain variable region comprising a CDR1 set forth as HYIMM (SEQ ID NO: 5), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO: 6), and a CDR3 set forth as RRIGVPRRDDFDI (SEQ ID NO: 53), a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO: 8), a CDR2 set forth as KASTLES (SEQ ID NO: 9), and a CDR3 set forth as QQYNTYWT (SEQ ID NO: 10); and
wherein the retinal disease is selected from the group consisting of diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO).

2. The method of claim 1 , wherein the retinal disease is DME.

3. The method of claim 1 , wherein the antibody has an apparent K i (K i,app ) lower than about 1 nM.

4. The method of claim 1 , wherein the light chain variable region further includes G57 in the framework region 3 (FR3).

5. The method of claim 1 , wherein the light chain variable includes N45 in the framework region 2 (FR2).

6. The method of claim 1 , wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

7. The method of claim 1 , wherein the antibody is a Fab.

8. The method of claim 1 , wherein the antibody is a human antibody.

9. The method of claim 1 , wherein the composition is administered via intravitreal injection.

10. The method of claim 1 , wherein the antibody is the only active agent administered to the subject for treating the retinal disease.

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Conley Gregory P
• Nixon Andrew
• Sexton Daniel J

Classifications

• A61K2039/54

  characterised by the route of administration · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07K2317/30

  characterized by aspects of specificity or valency · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K9/0051

  Ocular inserts or implants · CPC title